210 related articles for article (PubMed ID: 21947240)
1. [Nephrogenic systemic fibrosis (NSF): Effects of stricter guidelines on the use of contrast media containing gadolinium].
Hägele J; Simon M
Radiologe; 2011 Oct; 51(10):831-2. PubMed ID: 21947240
[No Abstract] [Full Text] [Related]
2. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
4. Current status of nephrogenic systemic fibrosis.
Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
[TBL] [Abstract][Full Text] [Related]
5. NSF: still relevant.
Thomsen HS
J Magn Reson Imaging; 2014 Jul; 40(1):11-2. PubMed ID: 24990765
[No Abstract] [Full Text] [Related]
6. Safety of magnetic resonance contrast media: a review with special focus on nephrogenic systemic fibrosis.
Haneder S; Kucharczyk W; Schoenberg SO; Michaely HJ
Top Magn Reson Imaging; 2015 Feb; 24(1):57-65. PubMed ID: 25654421
[No Abstract] [Full Text] [Related]
7. [Kidney and iodinated and gadolinium-based contrast agents].
Clément O; Faye N; Fournier L; Siauve N; Frija G
J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
[TBL] [Abstract][Full Text] [Related]
8. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
Young LK; Matthew SZ; Houston JG
Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
[TBL] [Abstract][Full Text] [Related]
9. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
Varela CU; Prieto-Rayo JC
Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
[TBL] [Abstract][Full Text] [Related]
10. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
Heverhagen JT; Krombach GA; Gizewski E
Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
[TBL] [Abstract][Full Text] [Related]
11. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe.
Leiner T; Kucharczyk W
J Magn Reson Imaging; 2009 Dec; 30(6):1357-63. PubMed ID: 19937935
[TBL] [Abstract][Full Text] [Related]
12. Use of Gadolinium in Individuals with Reduced Kidney Function.
Kalantari K; Swaminathan S
Clin J Am Soc Nephrol; 2021 Feb; 16(2):304-306. PubMed ID: 33431379
[No Abstract] [Full Text] [Related]
13. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
Thomsen HS
Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
[TBL] [Abstract][Full Text] [Related]
14. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
Idée JM; Fretellier N; Robic C; Corot C
Crit Rev Toxicol; 2014 Nov; 44(10):895-913. PubMed ID: 25257840
[TBL] [Abstract][Full Text] [Related]
15. [Nephrogenic fibrosing dermopathy or nephrogenic systemic fibrosis? What do we know and what do we have to learn?].
Ortega LM; Contreras G; Lenz O
Nefrologia; 2009; 29(2):109-17. PubMed ID: 19396315
[TBL] [Abstract][Full Text] [Related]
16. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
[TBL] [Abstract][Full Text] [Related]
17. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration.
Yang L; Krefting I; Gorovets A; Marzella L; Kaiser J; Boucher R; Rieves D
Radiology; 2012 Oct; 265(1):248-53. PubMed ID: 22923714
[TBL] [Abstract][Full Text] [Related]
18. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
19. Nephrogenic systemic fibrosis: a serious adverse reaction to gadolinium - 1997-2006-2016. Part 2.
Thomsen HS
Acta Radiol; 2016 Jun; 57(6):643-8. PubMed ID: 26802070
[No Abstract] [Full Text] [Related]
20. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
Dawson P
J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
[No Abstract] [Full Text] [Related]
[Next] [New Search]
